Learn More
Invitrogen™ IL-1 beta Monoclonal Antibody (ILB1-H6), Biotin
Mouse Monoclonal Antibody
Supplier: Invitrogen™ M420BB
Description
M420BB targets IL-1 beta in ELISA applications and shows reactivity with Human samples. The M420BB immunogen is recombinant human IL-1 beta. M420BB detects IL-1 beta which has a predicted molecular weight of approximately 31 kDa. The M420BB IL1b antibody (biotinylated conjugate of clone ILB1-H6) has successfully been paired as the detection antibody in a sandwich ELISA with capture antibody M421B (clone ILB1-H67). Typical dilutions for sandwich ELISA include 1 μg/mL for coating and 0.125 - 0.25 μg/mL for detection. Biotinylated antibody M420BB (clone ILB1-H6) and antibody M421B (clone ILB1-H67) have successfully been used in combination with recombinant IL1 beta protein SIL1B in ELISA applications.
Interleukin-1 beta (IL-1 beta) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. IL-1 beta is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1 beta into the active 17 kDa protein requires the activation of inflammasomes, which are multi-protein complexes that respond to pathogens, stress conditions, and other danger signals. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1 beta. IL-1 beta lacks a signal sequence peptide for classical ER/Golgi pathway and is secreted alongside caspase-1 via an alternate and incompletely understood mechanism. Although IL-1 beta is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions. IL-1 beta signals through two receptors, IL-1RI and IL-1RII, both of which are shared with IL-1 alpha. IL-1 beta activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. IL-1 beta play an important role in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses to infection and injury. Elevated levels of IL-1 beta have been associated with many chronic inflammatory conditions IL-1 beta neutralizing antibodies potential therapeutic value.
Specifications
IL-1 beta | |
Monoclonal | |
0.5 mg/mL | |
PBS with 4% BSA and proprietary Preservative | |
P01584 | |
IL1B | |
Recombinant human IL-1 beta. | |
250 μg | |
Primary | |
Human | |
Antibody | |
IgG1 κ |
ELISA | |
ILB1-H6 | |
Biotin | |
IL1B | |
catabolin; cytokine; Hematopoietin 1 (H1); IFN beta inducing factor; il 1b; IL 1β; IL-1; IL1 B; IL-1 beta; IL-1 precursor; IL1B; IL-1B; IL1B1; IL1beta; IL-1beta; IL1-BETA; IL1F2; IL1β; ILN; Interleukin; interleukin 1 beta; Interleukin 1 beta precursor; interleukin 1, beta; interleukin 1, beta 1; interleukin 1-beta; interleukin*1*beta; Interleukin1 beta; interleukin-1 beta; interleukin-1 beta precursor; interleukin-1 beta precursor (AA -113 to 153); interleukin-1 beta proprotein; interleukin-1b; interleukin-1beta; interleukin-beta; LAF; lymphocyte proliferation-potentiating factor; Osteoclast activating factor (OAF); preinterleukin 1 beta; Pro interleukin 1 beta; prointerleukin-1 beta; pro-interleukin-1-beta | |
Mouse | |
Protein G | |
RUO | |
3553 | |
-20°C | |
Liquid |
Your input is important to us. Please complete this form to provide feedback related to the content on this product.